Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection. Issue 9 (1st September 2016)

• Record Type: Journal Article
• Authors: Trang, Tracy P.; Dong, Betty J.; Kojima, Noah; Klausner, Jeffrey D.
• Is Part Of: Expert opinion on drug safety. Volume 15:Issue 9(2016)
• Page Start: 1287
• Page End: 1294
• Publication Date: 2016-09-01
• Subjects: Tenofovir disoproxil fumarate -- emtricitabine -- pre-exposure prophylaxis -- HIV -- prevention -- safety -- creatinine -- renal dysfunction -- bone mineral density; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2016.1211108
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors approved as pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). Prophylactic TDF-based regimens have been shown to reduce the risk of HIV infection by 74 to 92% among participants with detectable drug levels. Adverse events observed in clinical trials include nausea, elevated creatinine and liver enzymes, and decreased bone mineral density. Areas covered : This article reviews the pharmacology, pharmacokinetics, and the safety profile of TDF and FTC used as PrEP for HIV infection. Expert opinion : TDF-FTC can have a large impact in preventing HIV infections among high risk individuals when taken daily. Although TDF-FTC is associated with adverse events, they can be minimized with clinician-guided monitoring.